Therapeutic decisions under uncertainty for spinal muscular atrophy: The DECISIONS-SMA study protocol

• Published in: PloS one 2022-02, Vol.17 (2), p.e0264006-e0264006
• Main Authors: Saposnik, Gustavo, Díaz-Abós, Paola, Sánchez-Menéndez, Victoria, Álvarez, Carmen, Terzaghi, María, Maurino, Jorge, Brañas-Pampillón, María, Málaga, Ignacio
• Format: Article
• Language: English
• Subjects: Atrophy; Aversion; Behavioral economics; Biology and Life Sciences; Burnout; Burnout, Professional - epidemiology; Care and treatment; Caregivers; Clinical Decision-Making - methods; Clinical outcomes; Cross-Sectional Studies; Decision making; Decision theory; Disease Progression; Health risks; Health services; Herding; Humans; Inertia; Life expectancy; Life span; Medicine and Health Sciences; Muscular Atrophy, Spinal - therapy; Neurologists - psychology; Neurology; Neuromuscular diseases; Neurosciences; Occupational health; Patient Preference; Patients; Pediatrics; People and Places; Physical Sciences; Physicians; Pilot Projects; Preferences; Psychological aspects; Risk aversion; Social aspects; Social Sciences; Spinal muscular atrophy; Study Protocol; Uncertainty
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0264006

The therapeutic landscape for spinal muscular atrophy has changed in the last few years, encompassing respiratory/motor function and life expectancy benefits. However, physicians still have the challenge of tailoring individuals' treatment to therapeutic goals, disease progression, patient/caregiver's preferences, and personal experience to achieve an optimal risk/benefit balance. This study aims to provide insight into the preferred treatment choices of pediatric neurologists managing spinal muscular atrophy in their daily practice and to recognize behavioral factors that may influence decision-making. This is a noninterventional, cross-sectional pilot study involving 50 pediatric neurologists managing spinal muscular atrophy in Spain. We designed an online platform that contains 13 simulated case scenarios of common presentations of patients with spinal muscular atrophy. The primary study outcome will be treatment preferences according to the percentages of participants who select treatment initiation when recommended, switch therapies when there is evidence of disease progression, and select treatment discontinuation when disease progression puts patients outside treatment recommendation (11 case scenarios). Secondary outcomes include therapeutic inertia prevalence (11 case scenarios), herding phenomenon prevalence (2 case scenarios), care-related regret prevalence (specific questions) and intensity (10-item Regret Intensity Scale), occupational burnout prevalence (nonproprietary single-item measure), and risk preferences (uncertainty test and risk aversion assessment). The study findings will contribute to better understand relevant factors associated with therapeutic decisions of pediatric neurologists in spinal muscular atrophy, identifying treatment preferences and evaluating the role of behavioral aspects such as therapeutic inertia, herding, regret, and workplace burnout.